Adamis Pharmaceuticals Corporation

Company Review

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

  • Drug Manufacturers - Specialty & Generic
  • San Diego, California
Primary Stock Exchange Listings

Ticker Symbol:

ADMP

Nasdaq
United States

Stock Price

Latest Closing Price
0.54USD
Thu, 2 Jul 2020

Performance

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Valuation

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Health Check

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Financial Reports

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Similar Companies

↑ back to top